Skye H. Simpson

Targeting DNA Damage Response and Replication Stress in Pancreatic Cancer

Stephan B. Dreyer, Rosanna Upstill‐Goddard, Viola Paulus-Hock, Clara Paris et autres

BACKGROUND & AIMS: Continuing recalcitrance to therapy cements pancreatic cancer (PC) as the most lethal malignancy, which is set to become the second leading cause of cancer death in our society. The study aim was to investigate the association between DNA damage …

gb, fr, us, de, au (code pays fourni par la source)

HNF4A and GATA6 Loss Reveals Therapeutically Actionable Subtypes in Pancreatic Cancer

Holly Brunton, Giuseppina Caligiuri, Richard N. Cunningham, Rosanna Upstill‐Goddard et autres

Pancreatic ductal adenocarcinoma (PDAC) can be divided into transcriptomic subtypes with two broad lineages referred to as classical (pancreatic) and squamous. We find that these two subtypes are driven by distinct metabolic phenotypes. Loss of genes that drive endodermal lineage specification, HNF4A …

gb, ch, us, de, au (code pays fourni par la source)

Abstract CT210: Precision medicine for advanced pancreas cancer: the individualized molecular pancreatic cancer therapy (IMPaCT) trial

Lorraine A. Chantrill, Skye H. Simpson, Amber L. Johns, Mona Martyn-Smith et autres

Abstract Background: The Individualized Molecular Pancreatic Cancer Therapy (IMPaCT) trial is designed to exploit results from whole genome sequencing of pancreatic cancer collected under the auspices of the ICGC in Australia. Results showed that small subsets of patients had actionable changes in …

au (code pays fourni par la source)

Precision Medicine for Advanced Pancreas Cancer: The Individualized Molecular Pancreatic Cancer Therapy (IMPaCT) Trial

Lorraine A. Chantrill, Adnan M. Nagrial, Clare Watson, Amber L. Johns et autres

PURPOSE: Personalized medicine strategies using genomic profiling are particularly pertinent for pancreas cancer. The Individualized Molecular Pancreatic Cancer Therapy (IMPaCT) trial was initially designed to exploit results from genome sequencing of pancreatic cancer under the auspices of the International Cancer Genome Consortium …

au, gb (code pays fourni par la source)

Clinical and pathologic features of familial pancreatic cancer

Jeremy L. Humphris, Amber L. Johns, Skye H. Simpson, Mark J. Cowley et autres

BACKGROUND: Inherited predisposition to pancreatic cancer contributes significantly to its incidence and presents an opportunity for the development of early detection strategies. The genetic basis of predisposition remains unexplained in a high proportion of patients with familial PC (FPC). METHODS: Clinicopathologic features …

au, gb (code pays fourni par la source)

Precision Medicine for Advanced Pancreas Cancer: Early Lessons Learned from Negotiating the Pitfalls of a Molecular Therapeutics Trial in a Poor Prognosis Cancer

Lorraine A. Chantrill, Amber L. Johns, Clare Watson, Scott Mead et autres

Understanding how consumers would like to engage in the research decision-making process

Catherine Maree Holliday, Janice Kwok, Kimberley Yip, Cathy Axford et autres

There is an increasing emphasis on community and consumer engagement in cancer research, from identifying priorities to reviewing grants from a consumer perspective. It is clear that there is great interest from the community and consumers to be more actively involved in …

au (code pays fourni par la source)

Returning individual research results for genome sequences of pancreatic cancer

Amber L. Johns, David K. Miller, Skye H. Simpson, Anthony James Gill et autres

BACKGROUND: Disclosure of individual results to participants in genomic research is a complex and contentious issue. There are many existing commentaries and opinion pieces on the topic, but little empirical data concerning actual cases describing how individual results have been returned. Thus, …

au, gb (code pays fourni par la source)